Media Highlights and Announcements
Artrya’s CMO, Professor Girish Dwivedi, writes how CT scanning of the heart has changed how coronary artery disease can be assessed.
March 29, 2022
Artrya has opened a new US operation in Los Angeles. The company will market its AI-based solution, Artrya Salix, a device capable of analysing cardiac CT scans to illustrate a combination of coronary artery disease biomarkers.
Barron'sMarch 29, 2022
Australian medical technology company, today announces the formation of the Company’s American subsidiary, Artrya USA, Inc. (Artrya US)
The West AustralianMarch 29, 2022
Ted Schwab and Jory Tremblay have been appointed as co-CEOs of the company’s US subsidiary.
The Medical RepublicMarch 01, 2022
Dr Brendan Adler opinion piece on the need for an affordable and accessible option for treating patients with early coronary artery disease.
ausbizFebruary 08, 2022
John Barrington AM talks to ausbiz about the company’s strategy across the US, UK and Europe, and shares insights into the recent December quarter update.
Proactive InvestorsFebruary 05, 2022
John Barrington AM talks to Proactive Investor about the company’s appointment of Dr. Jacque Sokolov as Chair of Artrya’s Clinical Advisory Board.
Artrya Limited (ASX: AYA, Artrya or the Company) is today announcing the appointment of renowned healthcare executive Dr. Jacque J. Sokolov as Chair of Artrya’s Clinical Advisory Board.
Bio WorldNovember 30, 2021
Medtech newcomer Artrya Ltd. listed on the Australian Securities Exchange (ASX) in an AU$40 million (US$28.6 million) initial public offering.
The Motley FoolNovember 29, 2021
Move over Appen, the new AI player in town went gangbusters on its first day as a public company.